New COVID vaccine trial aims to outsmart evolving variants
NCT ID NCT07089706
First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times
Summary
This study tests an updated COVID-19 vaccine (mRNA-1283) designed to protect against current virus variants. About 832 people aged 12 and older, especially those at higher risk, will receive the vaccine. Researchers will measure immune response and monitor for side effects to ensure the vaccine is safe and effective.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
DelRicht Research-Atlanta
Atlanta, Georgia, 30329, United States
-
DelRicht Research-Baton Rouge
Baton Rouge, Louisiana, 70769, United States
-
DelRicht Research-Gulfport
Gulfport, Mississippi, 39503, United States
-
DelRicht Research-New Orleans
New Orleans, Louisiana, 70115, United States
-
DelRicht Research-Tulsa
Tulsa, Oklahoma, 74133, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Brain fog after COVID: can two common drugs clear it?
- Could a five-day pill course cut COVID-19 deaths? czech nationwide data puts molnupiravir to the test.
- Can COVID-19 and emergency surgery be safely managed together? a massive hospital study seeks answers
- Text or call? study tests best way to boost COVID shots in schools
- Fish oil and Body's own healing molecules could lift long COVID depression
- 13,000 volunteers shed light on who gets sick from COVID-19